mitoxantrone has been researched along with Chromosomal Translocation in 37 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17)(q22;q21) involving the PML and RARA genes is associated with exposure to agents targeting topoisomerase II (topoII), particularly mitoxantrone and epirubicin." | 7.76 | Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. ( Byl, JA; Chang, C; Corser, R; Felix, CA; Grimwade, D; Hasan, SK; Hoyle, C; Lo-Coco, F; Mays, AN; Osheroff, N; Parker, AN; Peniket, A; Saravanamuttu, K; Solomon, E; Wiemels, JL; Xiao, Y, 2010) |
| "Mitoxantrone is a DNA-topoisomerase 2 inhibitor used as a single agent for treatment of relapsing-remitting or progressive multiple sclerosis (MS)." | 7.74 | Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis. ( Baer, MR; Barcos, M; Chadha, MK; Heyman, MR; Ramkumar, B; Sait, SN, 2008) |
| "Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17)(q22;q21) involving the PML and RARA genes is associated with exposure to agents targeting topoisomerase II (topoII), particularly mitoxantrone and epirubicin." | 3.76 | Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. ( Byl, JA; Chang, C; Corser, R; Felix, CA; Grimwade, D; Hasan, SK; Hoyle, C; Lo-Coco, F; Mays, AN; Osheroff, N; Parker, AN; Peniket, A; Saravanamuttu, K; Solomon, E; Wiemels, JL; Xiao, Y, 2010) |
| " We characterized, at the genomic level, the t(16;21) translocation in a patient who developed t-AML after treatment of multiple sclerosis with mitoxantrone (MTZ)." | 3.75 | Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation. ( Amadori, S; Ammatuna, E; Bovetti, K; Chessa, L; Conte, E; Curzi, P; Divona, M; Ferrari, A; Grimwade, D; Hasan, SK; Lavorgna, S; Lo-Coco, F; Mays, AN; Montefusco, E; Noguera, NI; Ottone, T, 2009) |
| " However, cases are emerging after mitoxantrone therapy for multiple sclerosis (MS)." | 3.74 | Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. ( Amadori, S; Borlenghi, E; Byl, JA; Cattaneo, C; Cervera, J; Esteve, J; Felix, CA; Grimwade, D; Hasan, SK; La Nasa, G; Ledda, A; Lennard, A; Libura, M; Lo-Coco, F; Mays, AN; Melillo, L; Montefusco, E; Osheroff, N; Ottone, T; Sanz, MA; Satchi, G; Sperr, WR; Stephen, C; Voso, MT, 2008) |
| "We report two new cases of mitoxantrone-related leukemia occurring in two patients with multiple sclerosis (MS), 14 and 18 months after the last infusion of the drug." | 3.74 | Mitoxantrone-related acute leukemia in two MS patients. ( Gille, M; Goffette, S; Pielen, A; Sindic, CJ; Van Pesch, V, 2008) |
| "Mitoxantrone is a DNA-topoisomerase 2 inhibitor used as a single agent for treatment of relapsing-remitting or progressive multiple sclerosis (MS)." | 3.74 | Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis. ( Baer, MR; Barcos, M; Chadha, MK; Heyman, MR; Ramkumar, B; Sait, SN, 2008) |
| "Drug-induced cleavage of DNA by topoisomerase II mediates the formation of chromosomal translocation breakpoints in mitoxantrone-related APL and in APL that occurs after therapy with other topoisomerase II poisons." | 3.73 | DNA topoisomerase II in therapy-related acute promyelocytic leukemia. ( Adès, L; Blair, IA; Cassinat, B; Chomienne, C; Cross, NC; Felix, CA; Fenaux, P; Grimwade, D; Lafage-Pochitaloff, M; Mason, A; Mistry, AR; Osheroff, N; Parry, A; Peniket, AJ; Reiter, A; Segal, MR; Solomon, E; Walz, C; Whitmarsh, RJ; Wiemels, JL, 2005) |
| "We report the development of therapy-related early pre-B acute lymphoblastic leukemia in a patient administered a topoisomerase II inhibitor, etoposide, a consolidation therapy agent for acute promyelocytic leukemia." | 3.72 | MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia. ( Kondo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suemori, S; Suetsugu, Y; Sugihara, T; Tsujioka, T; Wada, H; Yamamori, S, 2003) |
| "Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2." | 3.70 | Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. ( Ashley, S; Kuan, A; Kulkarni, S; Mehta, J; Mitchell, P; Powles, R; Powles, T; Saso, R; Swansbury, GJ; Treleaven, J, 2000) |
| "Sixty-five patients with Stage I to III follicular lymphoma were randomized." | 2.71 | A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. ( Cabanillas, F; Cox, JD; Ha, CS; Lee, MS; McLaughlin, P; Mesina, OM; Rodriguez, MA; Romaguera, JE; Tucker, SL; Younes, A, 2005) |
| "All 35 patients were treated with the ANLL91 protocol consisting of etoposide, high-dose cytarabine, and anthracyclines." | 2.70 | Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group. ( Eguchi, M; Hayashi, Y; Hibi, S; Hongo, T; Imaizumi, M; Ishii, E; Isoyama, K; Kamada, N; Kawasaki, H; Kinukawa, N; Kosaka, Y; Mizutani, S; Nishimura, S; Oda, M; Oda, T; Okamura, T; Okawa, H; Tsukimoto, I, 2001) |
| "Patients with core binding factor acute myeloid leukemia (CBF-AML) benefit from more intensive chemotherapy, but whether both the t(8;21) and inv(16)/t (16;16) subtypes requires intensification remained to be determined." | 1.37 | Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). ( Bourquin, JP; Corbacioglu, S; Creutzig, U; Dworzak, MN; Reinhardt, D; Sander, A; Schrauder, A; Stary, J; Teigler-Schlegel, A; von Neuhoff, C; Zimmermann, M, 2011) |
| "This report describes a patient with Ollier disease and AML and may offer a clue into the genetic pathogenesis of these disorders." | 1.35 | Acute myelogenous leukemia associated with Ollier disease. ( Martin, PL; McLean, TW; White, MS, 2008) |
| "Treatment of acute promyelocytic leukemia (APL) with a combination of anthracycline-based chemotherapy and all-trans retinoic acid (ATRA) leads to very high rates of complete remission and survival." | 1.35 | Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia. ( Mellink, CH; Snijder, S; van der Lelie, H, 2008) |
| "Molecular relapse was detected in two patients by RQ-PCR four and six weeks, respectively before hematologic relapse occurred." | 1.33 | The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. ( Döhner, H; Döhner, K; Eiwen, K; Fröhling, S; Schlenk, RF; Scholl, C, 2005) |
| "Minimal residual disease was monitored by qualitative and real-time quantitative PCR." | 1.33 | Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. ( Astolfi, M; Boccadoro, M; Bodoni, CL; De Marco, F; Drandi, D; Gianni, AM; Guidetti, A; Ladetto, M; Magni, M; Mantoan, B; Matteucci, P; Pagliano, G; Ricca, I; Tarella, C; Zanni, M, 2006) |
| "However, minimal residual disease (MRD) detected with DEK/CAN chimeric m-RNA by reverse transcription polymerase chain reaction (RT-PCR) was continuously observed, although decreased quantitatively, following several courses of consolidation and intensification chemotherapies." | 1.30 | [The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation]. ( Ando, T; Ariyoshi, K; Hikiji, K; Kobayashi, M; Shinohara, K; Toyosawa, M, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (21.62) | 18.2507 |
| 2000's | 22 (59.46) | 29.6817 |
| 2010's | 6 (16.22) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Noguchi, R | 1 |
| Yoshimatsu, Y | 1 |
| Ono, T | 1 |
| Sei, A | 1 |
| Hirabayashi, K | 1 |
| Ozawa, I | 1 |
| Kikuta, K | 1 |
| Kondo, T | 2 |
| Yoon, S | 1 |
| Kim, H | 1 |
| Hur, M | 1 |
| Han, SH | 1 |
| Chung, HJ | 1 |
| Moon, HW | 1 |
| Yun, YM | 1 |
| Lee, MH | 1 |
| Ottone, T | 4 |
| Hasan, SK | 5 |
| Voso, MT | 2 |
| Ledda, A | 2 |
| Montefusco, E | 3 |
| Fenu, S | 1 |
| Pagoni, M | 1 |
| Hubmann, M | 1 |
| Lunghi, M | 1 |
| Platzbecker, U | 1 |
| Lo-Coco, F | 5 |
| Mays, AN | 4 |
| La Nasa, G | 1 |
| Cattaneo, C | 1 |
| Borlenghi, E | 1 |
| Melillo, L | 1 |
| Cervera, J | 1 |
| Stephen, C | 1 |
| Satchi, G | 1 |
| Lennard, A | 1 |
| Libura, M | 1 |
| Byl, JA | 2 |
| Osheroff, N | 3 |
| Amadori, S | 4 |
| Felix, CA | 3 |
| Sperr, WR | 1 |
| Esteve, J | 1 |
| Sanz, MA | 2 |
| Grimwade, D | 5 |
| Curzi, P | 1 |
| Chessa, L | 1 |
| Ferrari, A | 1 |
| Conte, E | 1 |
| Noguera, NI | 1 |
| Lavorgna, S | 1 |
| Ammatuna, E | 1 |
| Divona, M | 1 |
| Bovetti, K | 1 |
| Wang, H | 1 |
| Yang, W | 1 |
| Shao, H | 1 |
| Zhang, J | 1 |
| Qi, L | 1 |
| Liao, A | 1 |
| Li, Y | 1 |
| Liu, Z | 1 |
| Pielen, A | 1 |
| Goffette, S | 1 |
| Van Pesch, V | 1 |
| Gille, M | 1 |
| Sindic, CJ | 1 |
| Betancourt-García, RD | 1 |
| Castro, J | 1 |
| Fernández, AC | 1 |
| López-Enríquez, A | 1 |
| Fradera, J | 1 |
| Pacheco, E | 1 |
| Xiao, Y | 2 |
| Wiemels, JL | 3 |
| Saravanamuttu, K | 1 |
| Peniket, A | 1 |
| Corser, R | 1 |
| Chang, C | 1 |
| Hoyle, C | 1 |
| Parker, AN | 1 |
| Solomon, E | 2 |
| Schlenk, RF | 2 |
| Mitra, ME | 1 |
| Bernasconi, P | 2 |
| Di Raimondo, F | 1 |
| Stanghellini, MT | 1 |
| Marco, P | 1 |
| Döhner, H | 2 |
| Creutzig, U | 1 |
| Zimmermann, M | 1 |
| Bourquin, JP | 1 |
| Dworzak, MN | 1 |
| von Neuhoff, C | 1 |
| Sander, A | 1 |
| Schrauder, A | 1 |
| Teigler-Schlegel, A | 1 |
| Stary, J | 1 |
| Corbacioglu, S | 1 |
| Reinhardt, D | 1 |
| Cowell, IG | 1 |
| Austin, CA | 1 |
| Borker, A | 1 |
| Yu, L | 1 |
| Ode, D | 1 |
| Tsujioka, T | 1 |
| Wada, H | 1 |
| Yamamori, S | 1 |
| Otsuki, T | 1 |
| Suemori, S | 1 |
| Nakanishi, H | 1 |
| Suetsugu, Y | 1 |
| Mikami, M | 1 |
| Sugihara, T | 1 |
| Ferrer, A | 1 |
| Marcé, S | 1 |
| Bellosillo, B | 1 |
| Villamor, N | 1 |
| Bosch, F | 1 |
| López-Guillermo, A | 1 |
| Espinet, B | 1 |
| Solé, F | 1 |
| Montserrat, E | 1 |
| Campo, E | 1 |
| Colomer, D | 1 |
| Mistry, AR | 1 |
| Whitmarsh, RJ | 1 |
| Mason, A | 1 |
| Reiter, A | 1 |
| Cassinat, B | 1 |
| Parry, A | 1 |
| Walz, C | 1 |
| Segal, MR | 1 |
| Adès, L | 1 |
| Blair, IA | 1 |
| Peniket, AJ | 1 |
| Lafage-Pochitaloff, M | 1 |
| Cross, NC | 1 |
| Chomienne, C | 1 |
| Fenaux, P | 1 |
| Ha, CS | 1 |
| Cabanillas, F | 2 |
| Lee, MS | 1 |
| Tucker, SL | 1 |
| McLaughlin, P | 2 |
| Rodriguez, MA | 1 |
| Younes, A | 1 |
| Romaguera, JE | 1 |
| Mesina, OM | 1 |
| Cox, JD | 1 |
| Scholl, C | 1 |
| Eiwen, K | 1 |
| Fröhling, S | 1 |
| Döhner, K | 1 |
| White, MS | 1 |
| Martin, PL | 1 |
| McLean, TW | 1 |
| Ladetto, M | 1 |
| Magni, M | 1 |
| Pagliano, G | 1 |
| De Marco, F | 1 |
| Drandi, D | 1 |
| Ricca, I | 1 |
| Astolfi, M | 1 |
| Matteucci, P | 1 |
| Guidetti, A | 1 |
| Mantoan, B | 1 |
| Bodoni, CL | 1 |
| Zanni, M | 1 |
| Boccadoro, M | 1 |
| Gianni, AM | 1 |
| Tarella, C | 1 |
| Weisser, M | 1 |
| Haferlach, C | 1 |
| Haferlach, T | 1 |
| Schnittger, S | 1 |
| Snijder, S | 1 |
| Mellink, CH | 1 |
| van der Lelie, H | 1 |
| Ramkumar, B | 1 |
| Chadha, MK | 1 |
| Barcos, M | 1 |
| Sait, SN | 1 |
| Heyman, MR | 1 |
| Baer, MR | 1 |
| Hirt, C | 1 |
| Schüler, F | 1 |
| Kiefer, T | 1 |
| Schwenke, C | 1 |
| Haas, A | 1 |
| Niederwieser, D | 1 |
| Neser, S | 1 |
| Assmann, M | 1 |
| Srock, S | 1 |
| Rohrberg, R | 1 |
| Dachselt, K | 1 |
| Leithäuser, M | 1 |
| Rabkin, CS | 1 |
| Herold, M | 1 |
| Dölken, G | 1 |
| Haas, R | 2 |
| Moos, M | 2 |
| Karcher, A | 1 |
| Möhle, R | 1 |
| Witt, B | 1 |
| Goldschmidt, H | 1 |
| Frühauf, S | 1 |
| Flentje, M | 1 |
| Wannenmacher, M | 1 |
| Hunstein, W | 1 |
| Roulston, D | 1 |
| Anastasi, J | 1 |
| Rudinsky, R | 1 |
| Nucifora, G | 1 |
| Zeleznik-Le, N | 1 |
| Rowley, JD | 1 |
| McGavran, L | 1 |
| Tsuchida, M | 1 |
| Hayashi, Y | 2 |
| Todisco, E | 1 |
| Testi, AM | 1 |
| Avvisati, G | 1 |
| Moleti, ML | 1 |
| Cedrone, M | 1 |
| Cimino, G | 1 |
| Mancini, F | 1 |
| Mandelli, F | 2 |
| Inhorn, RC | 1 |
| Aster, JC | 1 |
| Roach, SA | 1 |
| Slapak, CA | 1 |
| Soiffer, R | 1 |
| Tantravahi, R | 1 |
| Stone, RM | 1 |
| Toyosawa, M | 1 |
| Shinohara, K | 2 |
| Ariyoshi, K | 2 |
| Ando, T | 1 |
| Kobayashi, M | 1 |
| Hikiji, K | 1 |
| Takeda, K | 1 |
| Kameda, N | 1 |
| Schulz, R | 1 |
| Martin, S | 1 |
| Benner, A | 1 |
| Gutiérrez, NC | 1 |
| García, JL | 1 |
| Chillón, C | 1 |
| Muntión, S | 1 |
| González, M | 1 |
| Hernández, JM | 1 |
| Knutsen, T | 1 |
| Rao, VK | 1 |
| Ried, T | 1 |
| Mickley, L | 1 |
| Schneider, E | 1 |
| Miyake, K | 1 |
| Ghadimi, BM | 1 |
| Padilla-Nash, H | 1 |
| Pack, S | 1 |
| Greenberger, L | 1 |
| Cowan, K | 1 |
| Dean, M | 1 |
| Fojo, T | 1 |
| Bates, S | 1 |
| Saso, R | 1 |
| Kulkarni, S | 1 |
| Mitchell, P | 1 |
| Treleaven, J | 1 |
| Swansbury, GJ | 1 |
| Mehta, J | 1 |
| Powles, R | 1 |
| Ashley, S | 1 |
| Kuan, A | 1 |
| Powles, T | 1 |
| Visani, G | 1 |
| Boni, M | 1 |
| Castoldi, GL | 1 |
| Ciolli, S | 1 |
| Clavio, M | 1 |
| Cox, MC | 1 |
| Cuneo, A | 1 |
| Del Poeta, G | 1 |
| Dini, D | 1 |
| Falzetti, D | 1 |
| Fanin, R | 1 |
| Gobbi, M | 1 |
| Isidori, A | 1 |
| Leoni, F | 1 |
| Liso, V | 1 |
| Malagola, M | 1 |
| Martinelli, G | 1 |
| Mecucci, C | 1 |
| Piccaluga, PP | 1 |
| Petti, MC | 1 |
| Rondelli, R | 1 |
| Russo, D | 1 |
| Sessarego, M | 1 |
| Specchia, G | 1 |
| Testoni, N | 1 |
| Torelli, G | 1 |
| Tura, S | 1 |
| Kawasaki, H | 1 |
| Isoyama, K | 1 |
| Eguchi, M | 1 |
| Hibi, S | 1 |
| Kinukawa, N | 1 |
| Kosaka, Y | 1 |
| Oda, T | 1 |
| Oda, M | 1 |
| Nishimura, S | 1 |
| Imaizumi, M | 1 |
| Okamura, T | 1 |
| Hongo, T | 1 |
| Okawa, H | 1 |
| Mizutani, S | 1 |
| Tsukimoto, I | 1 |
| Kamada, N | 1 |
| Ishii, E | 1 |
| Sarris, AH | 1 |
| Jiang, Y | 1 |
| Tsimberidou, AM | 1 |
| Thomaides, A | 1 |
| Rassidakis, GZ | 1 |
| Ford, RJ | 1 |
| Medeiros, LJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chemical Exposures and Leukemia Risks and Childhood Leukemia and Environmental Exposure[NCT00015587] | 3,523 participants (Actual) | Observational | 1995-04-30 | Completed | |||
| Phase 2 Study of Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission[NCT01050036] | 39 participants (Anticipated) | Interventional | 2010-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for mitoxantrone and Chromosomal Translocation
| Article | Year |
|---|---|
Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chromosome | 2009 |
Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Phytogenic; Antineoplastic Combine | 1995 |
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 1995 |
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromoso | 2001 |
4 trials available for mitoxantrone and Chromosomal Translocation
29 other studies available for mitoxantrone and Chromosomal Translocation
| Article | Year |
|---|---|
Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor.
Topics: Adult; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Collagen Type VI; Female; Gefiti | 2021 |
Do we still need morphologic evaluation in new era of advanced minimal residual disease analyses?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Hum | 2019 |
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Breakpoints; Chromosomes, Human, Pair 15; Chromosomes | 2014 |
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.
Topics: Adult; Antigens, Neoplasm; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; DNA; DNA Topois | 2008 |
Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation.
Topics: Core Binding Factor Alpha 2 Subunit; Cytogenetic Analysis; Databases, Genetic; Gene Expression Regul | 2009 |
Complex t(2;21;8)(p12;q22;q22): a variant t(8;21) in a patient with acute myeloid leukemia (AML-M2).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebral Hemorrhage; Chromosomes, Human, Pair | 2009 |
Mitoxantrone-related acute leukemia in two MS patients.
Topics: Adult; Analgesics; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; M | 2008 |
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Breast Neoplasms; Chromosomes, Human, Pair 15; Chromosomes, Huma | 2010 |
Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Breakpoints; Chromosomes, Human, Pair 15; Chromosomes | 2010 |
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Agents; Child; Chromosome Inversion; Chr | 2011 |
Do transcription factories and TOP2B provide a recipe for chromosome translocations in therapy-related leukemia?
Topics: Anthracyclines; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epir | 2012 |
Blast crisis of chronic myeloid leukemia: diagnosis prompted by T(8;9).
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplanta | 2002 |
MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Huma | 2003 |
Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Surviva | 2004 |
DNA topoisomerase II in therapy-related acute promyelocytic leukemia.
Topics: Antineoplastic Agents; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; DNA, Neoplasm; Doxorubic | 2005 |
The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromoso | 2005 |
Acute myelogenous leukemia associated with Ollier disease.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2008 |
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2006 |
Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy | 2007 |
Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Chromosomes, Human, Pair 11; Chromo | 2008 |
Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 11; Female; Humans; In Situ Hybridization, Fluoresce | 2008 |
Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosomes, Human, Pair 14; C | 1994 |
Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 10; Chromosomes | 1995 |
[The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 6; Chromosomes, | 1997 |
A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide.
Topics: Alkylating Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, | 1998 |
The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosomes, Hum | 1998 |
Cryptic insertion (15;17) in a case of acute promyelocytic leukemia detected by fluorescence in situ hybridization.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chr | 1999 |
Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Carrier Proteins; Chromosome Mapping; Chromosome Painting; | 2000 |
Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2000 |